NCT03161951

Brief Summary

Method for diagnostics of the origin of infections (bacterial vs viral) based on the identification of activation markers of blood neutrophils and monocytes will be developed.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
169

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2017

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 3, 2017

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 17, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 22, 2017

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 10, 2018

Completed
19 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 29, 2018

Completed
Last Updated

January 9, 2019

Status Verified

January 1, 2019

Enrollment Period

1.9 years

First QC Date

May 17, 2017

Last Update Submit

January 7, 2019

Conditions

Keywords

acute Infections, flow cytometry, cell activation

Outcome Measures

Primary Outcomes (2)

  • Sensitivity of the diagnosis of bacterial vs viral acute infection

    Sensitivity of the diagnosis of bacterial vs viral acute infection using proposed method

    1 month

  • Specificity of the diagnosis of bacterial vs viral acute infection

    Specificity of the diagnosis of bacterial vs viral acute infection using proposed method

    1 month

Study Arms (3)

Neuroinfections

Patients with acute neuroinfections of bacterial and viral ethology.

Intestinal Infectious Diseases

Patients with acute intestinal infectious diseases of bacterial and viral ethology.

Control group

Control group of healthy persons

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients admitted to the infectious departments of city hospitals.

You may qualify if:

  • neuroinfections or acute intestinal infections;
  • the possibility of blood sampling within a period of up to 24 hours from the moment of admission to hospital;
  • less than 72 hours passed after the onset of the disease and until blood was collected;

You may not qualify if:

  • refuse of patient to participate in the trial;
  • more than 24 hours passed after the patient entered the hospital;
  • the disease began more than 72 hours ago;
  • concomitant severe acute and chronic diseases;
  • malignant neoplasms, treatment at a time of less than 1 year, autoimmune diseases in the phase of exacerbation;
  • pregnancy/lactation;
  • HIV, Hepatites B/C;
  • active tuberculosis;
  • alcohol use disorder/drug addiction.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITHOUT DNA

Whole blood

Study Officials

  • Andrei Y Hancharou, Dr

    Head of the Laboratory for Immunology and Cellular Biotechnology, The Republican Research and Practical Center for Epidemiology and Microbiology

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of the Laboratory for Immunology and Cellular Biotechnology,

Study Record Dates

First Submitted

May 17, 2017

First Posted

May 22, 2017

Study Start

January 3, 2017

Primary Completion

December 10, 2018

Study Completion

December 29, 2018

Last Updated

January 9, 2019

Record last verified: 2019-01

Data Sharing

IPD Sharing
Will not share